Dramatic resolution of disseminated pyoderma gangrenosum associated with monoclonal gammopathy after therapy with bortezomib and dexamethasone

Pyoderma gangrenosum (PG) is an uncommon inflammatory and ulcerative skin disorder, which is commonly associated with systemic conditions such as inflammatory bowel disease, arthritis and haematological malignancies. It is widely stated that control of the underlying diseases may lead to resolution...

Full description

Saved in:
Bibliographic Details
Published in:International wound journal 2017-12, Vol.14 (6), p.1382-1384
Main Authors: Velasco‐Tamariz, Virginia, Carreño‐Tarragona, Gonzalo, Tous‐Romero, Fátima, Gil‐de la Cruz, Elena, Martín‐Clavero, Estela, Rivera‐Díaz, Raquel
Format: Article
Language:English
Subjects:
Case Report
Case Reports
Monoclonal gammopathies
Multiple myeloma
Neutrophilic dermatosis
Pyoderma gangrenosum
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pyoderma gangrenosum (PG) is an uncommon inflammatory and ulcerative skin disorder, which is commonly associated with systemic conditions such as inflammatory bowel disease, arthritis and haematological malignancies. It is widely stated that control of the underlying diseases may lead to resolution of PG. However, standard of care dictates that patients suffering with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (MM) should not receive therapy unless they progress to symptomatic MM. Here, we report a woman in her 40s with a disseminated corticodependent PG, resistant to any treatment attempted, including anti‐tumoral necrosis factor (TNF) therapy in which bortezomib–dexamethasone regimen results in dramatic healing of all lesions in only a month. This case supports the belief that treatment of the underlying monoclonal gammopathy could be necessary when PG presents as an aggressive, non‐responding skin disease.
ISSN:1742-4801
1742-481X
DOI:10.1111/iwj.12746